Showing posts with label UK. Show all posts
Showing posts with label UK. Show all posts

Tuesday, December 6, 2016

PubMed Update October/November 2016

43 papers this round, and there are some goodies in here for sure (don't miss #38!). Given the number and varied issues addressed, I divided them up into topic areas and, given the number on naloxone, I divided up the naloxone topic areas as well.



Naloxone interventions


Primary care

Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, Yonas H.
Subst Abus. 2016 Apr 19:1-6. [Epub ahead of print]
Comment: A pilot of naloxone co-prescribing.

Mueller SR, Koester S, Glanz JM, Gardner EM, Binswanger IA.
J Gen Intern Med. 2016 Oct 31. [Epub ahead of print]
Comment: Shows that naloxone for patients prescribed opioids must be appropriately framed.

Behar E, Rowe C, Santos GM, Coffa D, Turner C, Santos NC, Coffin PO.
J Gen Intern Med. 2016 Nov 4. [Epub ahead of print]
Comment: When actually implemented, providers really like adding naloxone to opioid-related care. One of five papers out of the Naloxone for Opioid Safety Evaluation of a naloxone co-prescribing study in San Francisco.


Wednesday, February 17, 2016

PubMed Update November 2015 - January 2016

We have 35 articles for your viewing this time, with apologies for the delay in getting this out. Thanks to Traci Green for offering to help out and for reviewing this post.


Becker WC, Merlin JS, Manhapra A, Edens EL.
Addict Sci Clin Pract. 2016 Jan 28;11(1):3. doi: 10.1186/s13722-016-0050-0.
Comment: Fascinating article. Worth a read if you’re interested in management of pain and opioids.

Harocopos A, Allen B, Paone D.
Int J Drug Policy. 2015 Dec 29. pii: S0955-3959(15)00374-6. doi: 10.1016/j.drugpo.2015.12.021. [Epub ahead of print]
Comment: Great to see some of the path from prescription opioids to heroin. Makes sense that first step is moving from a drug co-formulated with acetaminophen.

Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg A, Bernstein E.
Acad Emerg Med. 2016 Jan 27. doi: 10.1111/acem.12910. [Epub ahead of print]
Comment: To get EDs to enhance practices will require pressure from the top.

4) Internal Medicine Resident Knowledge, Attitudes and Barriers to Naloxone Prescription in Hospital and Clinic Settings.
Wilson JD, Spicyn N, Matson P, Alvanzo A, Feldman L.
Subst Abus. 2016 Jan 28:0. [Epub ahead of print]
Comment: Nice article from Baltimore finding that young physicians are ready and willing to prescribe naloxone, but aren’t routinely doing so yet.

Monday, July 27, 2015

PubMed Update March - May 2015

Three months. 46 papers. I’m already a month behind.

Dahlem CH, Horstman MJ, Williams BC.
J Am Assoc Nurse Pract. 2015 Mar 26. doi: 10.1002/2327-6924.12249. [Epub ahead of print]
Comments: Naloxone programs have been providing kits to settings where homeless people receive services for many years. This is a description of a program at a homeless health clinic.

Christoffersen DJ, Brasch-Andersen C, Thomsen JL, Worm-Leonhard M, Damkier P, Brøsen K.
Forensic Sci Med Pathol. 2015 Jun;11(2):193-201. doi: 10.1007/s12024-015-9673-9. Epub 2015 Mar 24.
Comments: It’s been awhile since we had a forensics paper here. I think this is a novel method of identifying enantiomers.

Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA.
Am J Public Health. 2015 May;105(5):e51-7. doi: 10.2105/AJPH.2014.302546. Epub 2015 Mar 19.
Comments: Stunningly low rate of drug overdose mortality in this cohort of prisoners in Georgia. This is one of the first times I’ve seen a paper on opioid overdose find radically different results in a different setting. I can’t access for details.

Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA.
Subst Abus. 2015 Mar 16:1-14. [Epub ahead of print]
Comments: A review toward the end of using community distribution data to build clinical care naloxone prescription.

Hser YI, Evans E, Grella C, Ling W, Anglin D.
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89. doi: 10.1097/HRP.0000000000000052.
Comments: This is a systematic review of long-term studies of opioid users. Among many fascinating data reported, the length of time not using a drug of choice increases the likelihood of continuing to not use that drug. This seems obvious to many, but I don’t believe it’s been documented before. Good read for anyone looking to understand some of the longitudinal outcome data.

Thursday, August 4, 2011

Program report: Training family members and loved ones to respond with naloxone

By Stephen Malloy

As you’ve read on this blog, programs that train drug users to respond to opiate overdose with naloxone are expanding across the globe. An important intervention that’s often overlooked, however, is training family members and “carers” - friends, housemates, and loved ones - of drug users to use naloxone. A program in the UK is doing just that, as Stephen Malloy reports:

In July 2009 the National Treatment Agency (NTA) supported a 16 site pilot project, entitled “overdose prevention and naloxone training for families and carers.” The pilot sites, which were spread across England, recruited and trained family members/carers of people at risk of opiate-related overdose death in overdose prevention; signs and symptoms of overdose; and naloxone administration and basic life support techniques. The family member/carer was also supplied with naloxone IF the person at risk of overdose was available to give written or oral consent for the supply to be made.

A new report shows that 495 family members/carers were trained, and at the time of its writing 20 lives had been saved thanks to naloxone use (18) and basic life support (2). These results demonstrate the need a wider circle of family/carers to be engaged around overdose prevention and crucially, be supplied with naloxone.

Friday, May 20, 2011

News: Wales to Expand Naloxone Distribution

The United Kingdom was one of the first countries to take up naloxone distribution as a strategy for reducing overdose deaths, with Scotland leading the way.  


The BBC reports that now, after the pilot "Take Home Naloxone" project that began in 2009, Wales plans to step up its naloxone efforts. Wales is estimated to be home to roughly 20,000 "problem drug users" - presumably injectors. Six hundred eighty four naloxone kits were distributed in the initial project, with 51 overdose reversals reported.